Goldman Sachs reverses engines on oil-price forecasts and raises the specter of $120 per barrel crude
In the span of just three months, Goldman Sachs analysts have gone from lowering their oil-price forecasts to hiking them.
Similar Posts
Reddit Joins S&P 500: What It Means for RDDT Stock
We research all brands listed and may earn a fee from our partners. Research and financial considerations may influence how brands are displayed. Not all brands are included. Learn more. Reddit, the internet’s most popular discussion forum, will join the S&P 500 on Tuesday, a milestone for the company just two years after it went…
Decisions taken by the Governing Council of the ECB (in addition to decisions setting interest rates)
July 2026 24 July 2026 External communication Publication of the 2026 ECB Convergence Report On 24 June 2026 the ECB published its Convergence Report assessing the progress made towards euro adoption in the Czech Republic, Hungary, Poland, Romania and Sweden, following its adoption by the General Council of the ECB. Prepared in accordance with Article…
How Steward Partners Builds Culture at Scale
Recorded on location at the Steward Symposium, Ryan Nauman welcomes Maria Condon, Chief of Staff at Steward Partners, to discuss how the firm’s culture is built, reinforced, and scaled amid rapid growth. Maria explains why the annual three-day symposium exists, what makes its energy and access to leadership unique, and how in-person connection complements content…
Waverly Advisors Acquires InVista, Adding $332M AUM
Waverly Advisors, an acquisitive Birmingham, Ala.-based registered investment advisor, has acquired InVista Advisors, a hybrid RIA previously affiliated with LPL Financial in Montgomery, Ala. The eight-person team manages about $332 million in assets under management and represents Waverly’s fifth location in the state. “InVista has built an outstanding reputation within the Montgomery market,” said Waverly…
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here’s Whether the Deal Is Worth It.
In the latest big-ticket deal in the pharmaceutical industry, Vertex Pharmaceuticals (VRTX 1.31%) and Crinetics Pharmaceuticals (CRNX +98.74%) announced in a joint press release that Vertex is acquiring Crinetics. This won’t come cheap, to put it mildly; it’s a premium-priced deal that will cost billions of dollars. Here’s a look at whether that’s likely to…
Choice Between Public and Private Healthcare Systems: Evidence from Veterans
For providing helpful comments and feedback, we thank David Beheshti, Robert Town, Todd Wagner, as well as seminar attendees and conference participants at the University of Tennessee, Annual Junior Health Economics Summit, ASHEcon, and the Southern Economics Association Meetings. We thank Sam Bock, Noah Boden-Gologorsky, Christopher Lim, Matthew Merrigan, Jonatas Prates, and Kemin Wang for…
